REMS Vendor Disruptions Prompt Greater US FDA Scrutiny
Executive Summary
McKesson’s exit from the space forced sponsors to switch vendors managing their REMS programs, which in some instances affected patient access to drugs. Omnibus legislation requires GAO report and collection of public input on factors FDA should consider in reviewing vendor changes.
You may also be interested in...
Isotretinoin iPLEDGE REMS Proposed Revisions To Get Two-Day AdComm Review
US FDA is once again considering changes to the Risk Evaluation and Mitigation Strategy for the acne medication, a year after modifications to the program caused disruptions in patient access.
US FDA Asks Manufacturers To Fix Disruption In Isotretinoin REMS
The agency offers ‘regulatory flexibility’ for certain requirements of the iPLEDGE REMS for the acne drug if manufacturers address delays in implementing the modified program.
Clozapine REMS Program Paused After Problems With Re-Certification
US FDA says pharmacists may dispense the antipsychotic without a REMS authorization and wholesalers may continue to ship it during temporary suspension of REMS. A high call volume and long wait times have impacted patient access since the modified REMS launched on 15 November.